Jon Krause
Obesity rates have been increasing in the US for decades, but in 2023 they fell – at least in part because of the burgeoning popularity of the “miracle drug” semaglutide. Approved for treating obesity only in 2021, it is in short supply and is very expensive, but it has already had an extraordinary impact (“How semaglutide and similar drugs work”, below).
Yet this could just be start. With many companies racing to market rival versions of semaglutide in cheaper and easier-to-take forms, as well as mounting evidence that that GLP-1 drugs can target a host of health conditions, the treatments…
